Mivavotinib, also known as TAK-659, is a highly potent, selective, reversible, and orally available dual inhibitor of FLT3 and of the spleen tyrosine kinase (Syk), and it is in clinical development for the treatment of patients with advanced solid tumors or hematologic malignancies. This evidence concerns the gene SYK and hematologic disorder.